Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population
Severe Heavy Metal Sensitivities: While not as clear-cut as Wilson's disease, a known, severe allergy or sensitivity to copper or other heavy metals is a major red flag
Theoretically, increased magnesium levels could result from concomitant use of potassium-sparing diuretics and magnesium supplements
He told us that: This is an important trial which reinforces the concept that patients with the [symptoms] of heart failure syndrome can be further benefited by administration of a drug that was originally developed to reduce blood sugar and has now emerged as an important way to reduce cardiovascular and heart failure events, while simultaneously improving patients functional capacity and sense of well-being. It also promotes weight loss, and was Studies have found that it may also lower cardiovascular risks for people with obesity
With whom will data be shared
Such approaches will enable the identification of more precise molecular markers of one-carbon metabolism dysfunction and its relationship to immune regulation
